Interferon Gamma-induced Protein 10 is Associated with Insulin Resistance and Incident Diabetes in Patients with Nonalcoholic Fatty Liver Disease

Overview

Journal Sci Rep

Specialty Science

Date 2015 May 12

PMID 25961500

Citations 31

Authors

Chia-Chu Chang

Chia-Lin Wu

Wei-Wen Su

Kai-Lun Shih

Der-Cherng Tarng

Chen-Te Chou

Ting-Yu Chen

Chew-Teng Kor

Hung-Ming Wu

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an important risk factor for the development of type 2 diabetes mellitus. Interferon gamma-induced protein 10 (IP-10), a proinflammatory chemokine, plays a crucial role in inflammatory diseases. This cross-sectional pilot study investigated whether circulating IP-10 is associated with the progression of liver disease, and prediabetes in patients with NAFLD. A total of 90 patients with NAFLD alone (n = 48) or NAFLD with incident diabetes (n = 42) and 43 controls participated in this study. Fasting plasma was used to assess metabolic parameters, inflammatory factors, endotoxin levels, and malondialdehyde (MDA) concentrations. Insulin resistance was estimated using homeostatic model assessment (HOMA-IR). IP-10 levels were significantly higher in patients with NAFLD alone (median (interquartile range): 369.44 (309.30-418.97) pg/mL) and in those with incident diabetes (418.99 (330.73-526.04) pg/mL) than in controls (293.37 (214.10-331.57) pg/mL) (P < 0.001). IP-10 levels were positively correlated with levels of alanine aminotransferase, hs-CRP, MDA, MCP-1, and TNF-α as well as HOMA-IR values. Ordinal logistic regression analysis revealed IP-10 was an independent risk factor associated with progressive liver injury, insulin resistance and incident diabetes. Circulating IP-10 may be a non-invasive biomarker for disease progression and subsequent diabetes development of NAFLD.

Citing Articles

Bariatric-induced microbiome changes alter MASLD development in association with changes in the innate immune system.

Shera S, Katzka W, Yang J, Chang C, Arias-Jayo N, Lagishetty V Front Microbiol. 2024; 15:1407555.

PMID: 39184030 PMC: 11342267. DOI: 10.3389/fmicb.2024.1407555.

IL-1β-Induced CXCL10 Expression in THP-1 Monocytic Cells Involves the JNK/c-Jun and NF-κB-Mediated Signaling.

Kochumon S, Al-Sayyar A, Jacob T, Arefanian H, Bahman F, Almansour N Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065674 PMC: 11279630. DOI: 10.3390/ph17070823.

Interferon Upregulation Associates with Insulin Resistance in Humans.

Adeva-Andany M, Carneiro-Freire N, Castro-Quintela E, Ameneiros-Rodriguez E, Adeva-Contreras L, Fernandez-Fernandez C Curr Diabetes Rev. 2024; 21(3):86-105.

PMID: 38500280 DOI: 10.2174/0115733998294022240309105112.

Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.

Cao L, An Y, Liu H, Jiang J, Liu W, Zhou Y BMC Med. 2024; 22(1):101.

PMID: 38448943 PMC: 10919055. DOI: 10.1186/s12916-024-03315-0.

Proteomic profiles of cytokines and chemokines in moderate to severe depression: Implications for comorbidities and biomarker discovery.

Watson K, Keller J, Spiro C, Satz I, Goncalves S, Pankow H Brain Behav Immun Health. 2024; 36:100731.

PMID: 38435722 PMC: 10906146. DOI: 10.1016/j.bbih.2024.100731.

References

Haukeland J, Damas J, Konopski Z, Loberg E, Haaland T, Goverud I . Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006; 44(6):1167-74. DOI: 10.1016/j.jhep.2006.02.011. View

Dumas M, Barton R, Toye A, Cloarec O, Blancher C, Rothwell A . Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006; 103(33):12511-6. PMC: 1567909. DOI: 10.1073/pnas.0601056103. View

Park S, Seo M, Shin H, Ryoo J . Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2012; 57(4):1378-83. DOI: 10.1002/hep.26183. View

Harte A, da Silva N, Creely S, McGee K, Billyard T, Youssef-Elabd E . Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond). 2010; 7:15. PMC: 2873499. DOI: 10.1186/1476-9255-7-15. View

Kasturiratne A, Weerasinghe S, Dassanayake A, Rajindrajith S, De Silva A, Kato N . Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol. 2012; 28(1):142-7. DOI: 10.1111/j.1440-1746.2012.07264.x. View

Clark J, Brancati F, Diehl A . The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98(5):960-7. DOI: 10.1111/j.1572-0241.2003.07486.x. View

Nielsen F, Mikkelsen B, Nielsen J, Andersen H, Grandjean P . Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem. 1997; 43(7):1209-14. View

Nalbantoglu I, Brunt E . Role of liver biopsy in nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20(27):9026-37. PMC: 4112884. DOI: 10.3748/wjg.v20.i27.9026. View

Younossi Z, Gramlich T, Matteoni C, Boparai N, McCullough A . Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004; 2(3):262-5. DOI: 10.1016/s1542-3565(04)00014-x. View

10.

Farrell G, Wong V, Chitturi S . NAFLD in Asia--as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013; 10(5):307-18. DOI: 10.1038/nrgastro.2013.34. View

11.

Zhang X, Shen J, Man K, Chu E, Yau T, Sung J . CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis. J Hepatol. 2014; 61(6):1365-75. DOI: 10.1016/j.jhep.2014.07.006. View

12.

Hu K, Wang H, Liu S, Liu C, Hung C, Bair M . Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol. 2014; 20(24):7718-29. PMC: 4069300. DOI: 10.3748/wjg.v20.i24.7718. View

13.

Palmer C, Corpuz T, Guirguis M, OToole S, Yan K, Bu Y . The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection. Gut. 2009; 59(3):397-404. DOI: 10.1136/gut.2008.165316. View

14.

Meier C, Chicheportiche R, Dreyer M, Dayer J . IP-10, but not RANTES, is upregulated by leptin in monocytic cells. Cytokine. 2003; 21(1):43-7. DOI: 10.1016/s1043-4666(02)00491-x. View

15.

Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Konigsrainer A . Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008; 138(8):1452-5. DOI: 10.1093/jn/138.8.1452. View

16.

Hintermann E, Bayer M, Pfeilschifter J, Luster A, Christen U . CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J Autoimmun. 2010; 35(4):424-35. PMC: 3855675. DOI: 10.1016/j.jaut.2010.09.003. View

17.

Adams L, Waters O, Knuiman M, Elliott R, Olynyk J . NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009; 104(4):861-7. DOI: 10.1038/ajg.2009.67. View

18.

Jackson M, Ahima R . Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin Sci (Lond). 2006; 110(2):143-52. DOI: 10.1042/CS20050243. View

19.

Kotronen A, Yki-Jarvinen H . Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2007; 28(1):27-38. DOI: 10.1161/ATVBAHA.107.147538. View

20.

Day C . Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005; 129(1):375-8. DOI: 10.1053/j.gastro.2005.05.041. View